Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | CA2 | P00918 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | TYR | P14679 | 1/20 | 0.45 |
| ▸ | HSPA5 | P11021 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.36 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.30 |
| ▸ | ATP2A2 | P16615 | 1/20 | 0.30 |
| ▸ | ATP2A3 | Q93084 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19729050 | 0.79 | CYP1A2 (0.38) | CYP2D6CYP1A2 | |
| SCHEMBL17865245 | 0.75 | SMN1; SMN2 (0.36) | SMN1; SMN2ALDH1A1CA2POLBTYR | |
| SCHEMBL13385205 | 0.73 | RAPGEF4 (0.35) | ALDH1A1POLBKDM4EMAPT | |
| SCHEMBL27519802 | 0.71 | SMN1; SMN2 (0.45) | SMN1; SMN2ALDH1A1CA2POLBTYR | |
| SCHEMBL17865231 | 0.70 | TSHR (0.30) | — | |
| SCHEMBL17865241 | 0.67 | TRPA1 (0.32) | — | |
| SCHEMBL7047479 | 0.66 | ALDH1A1 (0.62) | SMN1; SMN2ALDH1A1CA2POLBTYR | |
| SCHEMBL16413144 | 0.66 | TSHR (0.44) | ALDH1A1 | |
| SCHEMBL25857321 | 0.66 | TSHR (0.44) | ALDH1A1 | |
| SCHEMBL434782 | 0.64 | ALDH1A1 (0.59) | SMN1; SMN2ALDH1A1CA2POLBTYR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170360760-A1 | Inhibitors of Bromodomains | ZENITH EPIGENETICS CORP. (CA) | 2017-12-21 | — | — | US | disclosed |
| WO-2016097863-A1 | INHIBITORS OF BROMODOMAINS | ZENITH EPIGENETICS CORP. (CA) | 2016-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170360760-A1 | Inhibitors of Bromodomains | BRDT, BRD3, BRPF3 | SMN1; SMN2 3203/4885ALDH1A1 3551/4885CA2 4402/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.